Ledronin (Alendronate Sodium Trihydrate)

Alendronate sodium trihydrate binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, leading to reduced osteoclast activity and increased apoptosis, which slows bone breakdown.

The specific dose of Ledronin is determined by the prescribing healthcare professional based on the patient’s condition, renal function, and treatment goals. Dosage regimens may vary, and the prescriber will provide individualized instructions.

Safety of alendronate during pregnancy and lactation has not been established. It is classified as contraindicated unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To order Ledronin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ledronin belongs to the same class as other oral bisphosphonates such as risedronate and ibandronate. While all share the core mechanism of inhibiting osteoclast‑mediated bone resorption, differences exist in dosing frequency, potency, and specific safety profiles, which clinicians consider when selecting therapy.

Ledronin tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture, and avoid exposure to direct sunlight. Do not refrigerate or freeze the product.

Ledronin is taken orally as a whole tablet with a full glass of plain water, first thing in the morning on an empty stomach. After swallowing, remain upright for at least 30 minutes and avoid eating, drinking, or taking other medications during that period.

Serious adverse events include esophageal ulceration or severe irritation, osteonecrosis of the jaw, and atypical femur fractures. Patients should promptly report persistent chest pain, difficulty swallowing, jaw pain, or any unusual thigh pain to their healthcare provider.

Ledronin is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known esophageal disorders that delay emptying, hypersensitivity to alendronate or any tablet components, and those who cannot remain upright after dosing.